Abnormal accumulation of amyloid (A) and tau (T) are used to detect and stage AD [1] and can be ascertained from cerebrospinal fluid (CSF) markers, positron emission tomography (PET) and more recently, plasma markers [2], which are fast increasing in accuracy, sensitivity, breadth, and scalability [3]. Here, MAPT is linked to Alzheimer disease.